First-in-Human Phase I Study of SAR446523 in Relapsed/Refractory Multiple Myeloma

Sanofi is assessing subcutaneous SAR446523, an anti-GPRC5D ADCC-enhanced monoclonal antibody, in a first-in-human study of heavily pretreated MM patients. The trial will determine the safety profile, pharmacokinetics, and optimal dosing, potentially paving the way for a novel therapeutic option in the RRMM setting.